Accelrys Announces Comprehensive, Multi-Year Agreements with Several Industry-Leading Pharmaceutical Companies
"I am very pleased to report that our efforts to modernize our architecture and improve product quality, along with an intense focus on customer satisfaction, have successfully led to the signing of a number of comprehensive, multi-year agreements with our customers," said Mark J. Emkjer, President and Chief Executive Officer of the Company. Mr. Emkjer concluded, "We believe that the collective magnitude of these agreements and their duration validate the significant value that our solutions bring to our customers."
“I am very pleased to report that our efforts to modernize our architecture and improve product quality, along with an intense focus on customer satisfaction, have successfully led to the signing of a number of comprehensive, multi-year agreements with our customers”
Statements contained in this press release relating to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future, including statements relating to the Company's products and demand therefore and certain of the statements of Mr. Emkjer, are forward-looking statements. The Company's actual results could differ materially from those projected in these forward-looking statements. In particular, the Company's products may not be successfully completed or developed or may not achieve market acceptance or demand. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2005 and the Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2005 and September 30, 2005. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Scitegic, Inc., a wholly owned subsidiary of Accelrys, has pioneered a new technology platform called "data pipelining" to process research discovery data with unprecedented flexibility. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. Its materials research and development team is based at its European Headquarters and Centre of Excellence in Cambridge, UK. For more information about Accelrys, visit its website at http://www.accelrys.com/.